# Hedge-Fund Skeptic Critique — Deck v1

Reviewer frame: PhD quant, bond-side RQS, predisposed to hate pop-behavioral-finance, will ask the hardest possible version of every question. Read the deck, knowledge files 05/06/07/10, and the pre-identified question lists. Below is what I would actually do to this presenter in Q&A.

---

## Overall impression

The science is better than the average "neuroscience for finance" talk and the convergence framing is legitimately stronger than a single-discipline pitch, but the deck embeds at least three load-bearing claims that will not survive a sharp quant in the room: (a) the "cortisol causally flattens utility → therefore 2022 horizon compression is an HPA biomarker" syllogism confuses a lab-dose intervention with an observational text signal and has no out-of-sample validation, (b) the "five disciplines converge" visual on slide 3 is a presentation device that will read as post-hoc pattern-matching because no discipline makes a *dissociating* prediction, and (c) the deck is written as if the audience traded equities on a floor — almost none of the bond-specific behavioral-pricing machinery from knowledge/05 (intermediary asset pricing, dealer balance-sheet constraints, 2022 Treasury-market dislocation) makes it to the main slides. The recommendations are reasonable in direction but wildly over-engineered on the evidence shown.

## The killer questions you would ask in Q&A

**1. "Show me the NLP validation set. What's the inter-rater agreement between your model's confidence score and human coders on a held-out sample, and what's the correlation between that extracted score and any independently measured behavioral outcome — position size, trade conviction, anything?"**
Why devastating: the entire deck rests on a scalar extracted from text. Slide 4's per-analyst normalization only matters if the extracted scalar is actually measuring what the deck claims. If the answer is "we prompted an LLM and eyeballed the results," everything downstream collapses. What the presenter should say: point to an appendix slide with (a) annotator κ, (b) test-retest on held-out analyst samples, (c) a validation target — ideally correlation with blind-human ratings AND with a behavioral outcome. If that appendix doesn't exist, build it before the talk.

**2. "You have three findings across how many analysts, how many notes, how many tests? What's the family-wise error rate, and how many findings survive Bonferroni or BH correction?"**
Why devastating: the deck asserts convergence but never quantifies the multiple-comparisons burden. A1a/b/c and B1, per-analyst panels, tail-decile regressions, stress-window splits — this is dozens of implicit tests. Presenter should pre-empt with a slide reporting p-values after correction, ideally pre-registered hypotheses, and an honest statement of which findings are robust to BH at q=0.05.

**3. "Fleming 2010 is N=32. Coates-Herbert is N=17, male-only, one desk. Kandasamy is N=36. Coates 2009 2D:4D is N=44, male-only, R²=0.55. You would reject any factor paper with that sample from your own research team — what's your basis for accepting these?"**
Why devastating: these are the deck's mechanism citations. Each is individually underpowered and several have replication problems. The 2D:4D literature in particular has taken a beating post-replication-crisis (Apicella et al. failed replications of digit-ratio/risk studies; broader meta-analyses find effect sizes an order of magnitude smaller than Coates 2009). Presenter should say: "I agree — no single one of these is sufficient. The argument is the *joint* posterior across independent small studies plus two large convergent literatures (metacognition corpus, HPA physiology). Here is a slide of the replication status of each anchor study." And then actually have that slide.

**4. "The Kandasamy experiment dosed subjects with cortisol for 8 days and measured utility curvature change. You are inferring that 2022's horizon compression is 'an HPA episode' from text alone, with no cortisol measured. What's the distinguishing prediction between your HPA-biomarker hypothesis and (a) analysts rationally updating their priors to a higher-volatility regime or (b) analysts writing defensively because their PM clients are asking for short-horizon calls?"**
Why devastating: this is the core causal-inference weakness. Kandasamy is a causal experiment on utility, not on writing. The deck's slide 8 takeaway — "The 2022 analyst note is a non-invasive biomarker of an HPA episode" — is an inference with no biomarker validation in the actual analyst population. Presenter should concede the observational nature, propose a falsifiable test (cortisol swabs or HRV on a subset of active analysts during the next stress window), and frame the current claim as consistent-with rather than identifies.

**5. "Knowledge file 07 gives you the clean computational restatement: under an HGF, inferred volatility rises and the effective horizon 1/volatility collapses. That is a *rational Bayesian response* to a regime change, not a bias. How do you tell 'correct volatility-inference' from 'stress-driven over-precision on threat priors'? They predict the same text output."**
Why devastating: this is the presenter's own knowledge file being turned against them. The rational-Bayesian-update and the aberrant-precision interpretations are observationally identical in aggregate text; they diverge in (a) post-stress recovery asymmetry, (b) moderator by working-memory / tenure (Otto 2013), (c) individual-level cortisol correlation. If the deck is going to invoke the computational frame as a strength, it has to honor its own falsifiability requirement.

**6. "Your slide 3 says five disciplines converge. I count five disciplines making the *same directional prediction*, which is not convergence — it's consonance. Convergence requires each discipline to make a *dissociating* prediction that the others can't. Which discipline's prediction, if violated by your data, would falsify the finding?"**
Why devastating: "convergence" is the rhetorical spine of the talk and it is being used loosely. Real cross-disciplinary convergence (e.g. the independent optical/radio/gravitational-wave detection of GW170817) is impressive because each probe carries dissociating information. The deck's version is: five literatures all say "stress compresses decision horizons." That's the *same* claim, not convergence. Presenter should either (a) reframe slide 3 as "consistent evidence across five literatures, each with its own failure modes" or (b) identify a genuinely dissociating prediction per discipline and add a slide.

**7. "Slide 13 claims 'process beats self-awareness,' invoking the Haynes surgical checklist cutting mortality 47%. That study had a pre/post design across 8 hospitals with no control group — Urbach 2014 NEJM, a controlled Ontario rollout, found no mortality benefit. Why is a pre/post result with a known implementation-fidelity problem in your deck at all, let alone as the headline number?"**
Why devastating: Haynes 2009 is the load-bearing evidence for process-over-awareness, and Urbach 2014 is the known null replication. Knowledge/06 actually notes the Urbach issue; the deck does not. Presenter should acknowledge Urbach explicitly in the speaker notes for slide 13 and have an appendix slide showing (a) pre-post vs. RCT evidence and (b) the Pronovost central-line result which is more robust.

**8. "Morewedge 2015 reports 20–30% bias reduction on crafted test items. What's the evidence any of that transfers to portfolio P&L? Because if the transfer evidence is the Sellier 2019 MBA field study with N=290 undergrads on a Challenger-decision case, I'm going to say you're recommending a re-organization of our decision pipeline on evidence that has never been tested in an investment context."**
Why devastating: it's exactly right. Knowledge/06 is candid that "transfer evidence is still thin — one field experiment on MBAs." The deck is not candid about that. Presenter should explicitly frame the recommendations as *mechanism-plausible and process-analogue* rather than *effect-size-calibrated-for-investment*, and flag the RQS opportunity to be the first-movers with an actual A/B test.

**9. "Your Coates 2009 2D:4D R²=0.55 claim on slide 10 is from N=44 male traders at one London HFT firm in one year. That's not just underpowered — it has been repeatedly non-replicated in subsequent trader and general-population samples, and the broader 2D:4D-risk literature meta-analyzes down to d~0.1. Why is this on a recommendation slide at all?"**
Why devastating: the R²=0.55 is a *very* suspicious number — it's the kind of effect size that usually signals either a winner's-curse-inflated first report or a specification-search problem. A bond quant will know the replication literature on digit-ratio. Presenter should either drop the number and keep a qualitative "testosterone-mediated risk-taking" reference, or explicitly label it as a single-study finding pending replication.

**10. "The DST market anomaly (Kamstra-Kramer-Levi 2000) was challenged by Pinegar 2002 on multiple-comparisons grounds and has inconsistent out-of-sample evidence. Your slide 3 lists DST as a data point in the chronobiology column. Are you asking me to accept a disputed equity-market anomaly as mechanism evidence for bond PM stress?"**
Why devastating: yes, the DST anomaly is contested; any chronobiology-to-markets citation needs honest framing. Presenter should either remove DST from the convergence grid or flag it as disputed, and lean on the within-subject sleep-PFC literature (Yoo 2007) which is more defensible.

**11. "Your audience trades bonds. Coates was equity HFT, Kandasamy was lab subjects, Fleming was perceptual metacognition, Hermans used aversive movie clips. How much of this evidence base has any bond-market anchor at all?"**
Why devastating: the mechanism citations are all equity/lab, and the bond-specific material in knowledge/05 (intermediary asset pricing, Treasury market depth 2022, UK gilt crisis, credit-cycle over-extrapolation) is missing from the main deck. An RQS bond audience will notice. Presenter needs at minimum one slide translating each mechanism to a bond-market channel: horizon compression → Duffie slow-moving capital, fight/flight → dealer-balance-sheet VaR limits, sleep/schedule → FOMC/CPI policy-window P&L patterns.

**12. "Knowledge file 05 gives you the Duffie, Brunnermeier-Pedersen, He-Krishnamurthy intermediary-asset-pricing story. These are *rational structural* mechanisms, not behavioral ones. How do you tell a 2022 rates analyst's 'HPA-driven horizon compression' apart from a rational update that their firm's balance sheet capacity just shrank because duration VaR went through the roof?"**
Why devastating: the behavioral and intermediary-capital stories are observationally collinear in crisis windows. Fama 1998 would say they're indistinguishable in normal periods. Presenter should explicitly adopt the AMH framing from their own knowledge/05: both are true, relative weight is regime-dependent, and the RQS value-add is the *regime classifier*, not the behavioral story as a standalone.

**13. "What does this change about my Monday morning? Give me the incremental Sharpe of the tail-weighted sizing band versus a naive equal-weighted sizing band on your own historical data, with the confidence interval."**
Why devastating: this is the quant's version of "so what?" If the presenter can't produce a backtest of recommendation #2 (tail-weighted sizing) on the internal dataset — which they have — the recommendations are hypotheses, not findings. Presenter needs one slide showing expected tracking-error/Sharpe uplift with an honest CI.

**14. "Slide 12 claims 'the instrument layer is closer than people think — HRV and pupillometry in wearables.' Where's the published evidence that HRV or pupil dilation improves a trading decision in a professional setting? I'm aware of the neurovisceral-integration basic science. I'm asking about transfer."**
Why devastating: knowledge/08 and slide 12's own caption admit "no published continuous HRV + pupil + market-telemetry panel in professional PMs." The deck frames this gap as an RQS opportunity, which is fine rhetorically, but slide 12's takeaway — "the instrument layer for this thesis is closer than people think" — overclaims. Presenter should soften the takeaway to "the measurement technology is mature in basic-science contexts; translation to PM telemetry is an open research frontier, not a shovel-ready implementation."

**15. "You said analysts in 2022 had their horizons collapse. Did the analysts who were fired or left in 2022 stay in your sample? If they're out, you have a survivor bias on the horizon-compression finding in the exact direction that makes the finding look stronger than it is."**
Why devastating: it's a clean methodological gotcha and it has nothing to do with the science — it's about the empirical design the deck is about to show. The presenter must have a one-liner answer (in-sample / out-of-sample / both, and a robustness check either way) before walking on stage.

---

## Weakest claims in the deck, ranked

**1. Slide 8 takeaway — "The 2022 analyst note is a non-invasive biomarker of an HPA episode. Text output is a proxy for a well-characterized neuroendocrine state."**
Why vulnerable: "biomarker" is a clinical-validation term. To call something a biomarker of HPA activation, you need either concurrent cortisol/HRV on the same individuals or a prospectively validated text-to-cortisol mapping. The deck has neither. This is the single most aggressive over-claim in the deck.
What to say instead: "The 2022 horizon compression is *consistent with* the behavioral signature of HPA-axis activation documented under cortisol dosing (Kandasamy 2014). We are not claiming text alone identifies an HPA episode; we are proposing a hypothesis that future paired biometric + text collection can test."

**2. Slide 3 framework — "When five independent peer-reviewed disciplines predict the same result and our data shows it, the conclusion is not a single-field coincidence. Convergence is the argument."**
Why vulnerable: the disciplines don't independently predict — they draw on overlapping underlying mechanisms (HPA, catecholamines, PFC). Citing psychology/neuroanatomy/endocrinology/computational/evolutionary/chronobiology for the same HPA pathway is one mechanism described at five levels, not five independent predictions.
What to say instead: "Five disciplinary vocabularies describe the same underlying pathway at different levels of analysis. The argument is not statistical independence; it is *mechanistic integration*." This is weaker but defensible.

**3. Slide 10 caption — "Coates 2009 PNAS 2D:4D explains R²=0.55 of trader P&L variance."**
Why vulnerable: N=44, male-only, one firm, contested replication status, enormous effect size that has not held up in subsequent work.
What to say instead: drop the number entirely; keep the reference as "Coates and colleagues have reported prenatal-androgen markers associating with trader risk-taking," qualified as "first-generation finding with limited replication."

**4. Slide 13 recommendation 3 — "Haynes surgical checklist cut mortality 47%."**
Why vulnerable: pre/post design, no controls, Urbach 2014 NEJM found no benefit in controlled Ontario rollout.
What to say instead: "Process-level checklists have demonstrated large effects in pre/post designs (Haynes 2009) and the most robust controlled evidence comes from Pronovost 2006 central-line infection reduction. Implementation fidelity matters; checklists implemented as theater do not produce effects."

**5. Slide 12 takeaway — "The instrument layer for this thesis is closer than people think — and the research gap is an opportunity, not a limitation."**
Why vulnerable: reframing "no published evidence" as "opportunity" is the kind of thing that gets a skeptic's pen moving. There *is* a published gap; owning it is stronger than spinning it.
What to say instead: "Continuous PM biometrics is an open research frontier. Capital Group is positioned to produce the first-mover evidence." Same idea, less spin.

**6. Slide 13 takeaway — "None of these four instruments depends on people being less biased. They absorb known biases as design parameters — the only form of debiasing that reliably works in experts under stress."**
Why vulnerable: "the only form that reliably works" is a strong monotype claim. Knowledge/06 explicitly says "Layered interventions (training + process + feedback) outperform any single lever" and discusses process interventions that fail (Urbach). The deck softens "Kahneman's late-career view" into a universal rule.
What to say instead: "Process interventions have the best risk-adjusted evidence for durable bias-reduction in expert populations; the deck's recommendations are designed to layer on top of existing analyst training rather than replace it."

**7. Slide 6 takeaway — "The middle of an analyst's confidence distribution is noise. The tails are signal."**
Why vulnerable: the DDM/SDT proof (Sanders-Hangya-Kepecs) is for a *Bayesian-calibrated reporter*. It is an *if-then* theorem, not an empirical regularity. The deck uses theorem status as if it bypassed the empirical question of whether Capital Group analysts actually behave as Bayesian reporters.
What to say instead: "Signal-detection theory predicts that a Bayesian-calibrated reporter's accuracy is U-shaped in reported confidence. Our finding that the U-shape is present is the empirical signature that our analysts are approximately Bayesian. Analysts for whom the U-shape doesn't appear may need individualized diagnosis."

**8. Slide 4 takeaway — "Per-analyst normalization is not statistical convenience — it's the only way to recover a cross-analyst signal..."**
Why vulnerable: "only way" is too strong. Mixed-effects models with analyst random effects do the same thing while preserving absolute-level information. Percentile-within-analyst is one valid route; so is GLMM.
What to say instead: "Per-analyst normalization — whether via percentile-within-analyst or analyst-random-effects — is required to recover the biological signal. The deck uses percentile for display clarity."

**9. Slide 3 row "A1a/A1b" citations conflating heterogeneity and tail-signal.**
Why vulnerable: A1a is about *why distributions differ across analysts* (heritable, neuroanatomical, linguistic). A1b is about *why the tails carry signal* (SDT, OFC X-pattern). Lumping them in one row treats different mechanisms as one convergent prediction.
What to say instead: split the row into two.

**10. Slide 13 rec #4 — "Sleep & scheduling policy around high-stakes decisions… Yoo 2007: sleep loss amplifies amygdala reactivity 60%."**
Why vulnerable: Yoo 2007 is N~26 total-sleep-deprivation study. Translating to "avoid major reallocations on sleep-deprived days" is reasonable mechanism-level; calling sleep "the highest-leverage lever in this entire deck" needs a quantitative anchor from PM data, which the deck does not provide.
What to say instead: keep the recommendation, drop the superlative.

---

## Missing content that would defend the thesis

The appendix needs, at minimum:

- **NLP validation deck.** Prompt / model / version, held-out sample, human inter-rater agreement (κ), correlation with a behavioral outcome (PM conviction rating, trade size, realized turnover). Include a direct test for temporal drift of the model across the 2018–2024 window — did the LLM's confidence-extraction behavior shift when the underlying LLM was upgraded?
- **Pre-registration / multiple-comparisons slide.** Which findings were hypothesized a priori, which were discovered. Family-wise corrected p-values. Honest accounting of how many per-analyst sub-analyses were run.
- **Selection-effects slide.** Analysts who entered/exited sample by year, total head-counts, sensitivity of key findings to the 2022-active subsample vs. full panel.
- **Base-rate / prior-stress-windows slide.** Horizon compression measured in 1994, 2008, 2013 taper tantrum, 2020 COVID, 2022. Is 2022 actually different from the others, or is it just the most recent?
- **Bond-mechanism translation slide.** One table mapping each behavioral finding to a bond-market transmission channel: horizon compression → slow-moving capital (Duffie), flight → dealer-VaR tightening (He-Krishnamurthy), correlated de-risking → liquidity spirals (Brunnermeier-Pedersen), credit-cycle over-extrapolation → Greenwood-Hanson issuer-quality signal.
- **Rational-alternative slide.** For each behavioral claim, the nearest rational-frictions alternative and what empirical signature would distinguish them.
- **Out-of-sample / CV slide for tail-weighted sizing.** Backtest of recommendation #2 on internal data with confidence bands. Sharpe uplift, tracking-error impact, implementation-cost haircut.
- **Replication-status table for anchor studies.** Fleming 2010, Coates-Herbert 2008, Coates 2009 2D:4D, Kandasamy 2014, Yoo 2007, Haynes 2009 — each with N, replication attempts, status (robust / mixed / contested / null).
- **AMH framing slide.** Lo Adaptive Markets Hypothesis as the meta-frame, as knowledge/05 explicitly recommends.
- **Moderator analysis on horizon compression.** Does tenure / working-memory proxy / sleep diary (if available) moderate, as Otto 2013 would predict? This is the computational-model falsifiable test the deck gestures at but doesn't execute.
- **Cortisol / HRV pilot plan.** If the thesis is "biomarkers are measurable," show an actual pilot plan with N, window, instruments, and pre-registered primary endpoint. Concrete beats conceptual.

## "This is pop-behavioral-finance" red flags

**Slide 1 hook — "the written time horizons of our rates analysts *collapsed* — at exactly the moment the market needed longer thinking."**
The italicized "collapsed" plus "exactly the moment" is the narrative-economics voice, not the quant voice. A skeptic reads "exactly" as hand-waving and "collapsed" as loaded language. Rephrase: "In 2022, a statistically significant shortening of analyst-note time horizons coincided with the largest rates drawdown since 1973."

**Slide 2 thesis — "The frame is not 'understand yourself and you'll decide better.' The frame is 'measure the bias, build the tool...'"**
The contrast to "understand yourself" is a straw man. Nobody in a quant RQS room believes the naive self-awareness thesis. Drop the framing contrast; state the instrument thesis directly.

**Slide 3 takeaway — "Convergence is the argument."**
Slogan-grade, appears tautological. A skeptic hears "I don't have a statistical argument so I'm calling it convergence." Support with a specific dissociating prediction per discipline or reword.

**Slide 10 B1 caption — "The decomposition is not a metaphor — it's anatomy: fight (dorsomedial PAG drives active defense, approach, aggression; testosterone-mediated...), flight (dorsolateral PAG drives escape/avoidance; cortisol-mediated, benchmark-hugging in a PM)..."**
Mapping "benchmark-hugging PM" to "dorsolateral PAG flight circuit" is a just-so-story. The PAG fight/flight machinery was characterized in rodent electrical-stimulation work; there is no published evidence a PM selling into a benchmark activates dorsolateral PAG. This is exactly the kind of claim Gould-Lewontin would flag. Reframe as "the *functional decomposition* (approach / avoid / no-trade) has a neural analog in PAG circuits; we are *not* claiming PM benchmark-hugging is a PAG-circuit read-out."

**Slide 10 takeaway — "The mechanism is biological, not motivational. Which means the lever is biological too — not willpower, not self-talk, but the design of the environment around the decision."**
"Mechanism is biological not motivational" is a false dichotomy — motivational states *are* biological. Presenter means "the lever operates at the environmental design level, not the self-awareness level." Say that.

**Slide 12 eyebrow — "Measurement is closer than people think."**
The anti-skeptic rhetorical register ("closer than people think"). A quant reader assumes the opposite.

**Slide 14 close — "Three biases. Five disciplines converge. Four instruments."**
Three-five-four is a TED-talk triplet. The substance is fine but the format reads as inspirational. An RQS audience will close the deck thinking "that was slick" rather than "that was rigorous."

## Bond-market specificity gaps

- **Slide 1** anchors on Bloomberg Treasury and long-zero returns. Good. But every *mechanism* slide after that is equity-or-lab. No bridge.
- **Slide 8 (A1c science)** cites Kandasamy, Arnsten, Schwabe-Wolf, Yoo. None has been tested on bond markets. Knowledge/05 has the Vayanos-Vila preferred-habitat and He-Krishnamurthy crisis-dynamics results that are the *actual* bond-market literature on stress-state pricing. Missing.
- **Slide 9 (market-level) was dropped in the 14-slide deck.** The 11-slide EXECUTIVE_SUMMARY includes a "Market-level read: psychology aggregates into mispricing" slide (Stambaugh-Yu-Yuan or Haddad-Moreira-Muir). The 14-slide deck.html has no such slide. The strongest bond-specific material — intermediary asset pricing, Haddad 2020 corporate-bond ETF dislocation, credit-cycle over-extrapolation — is sitting in knowledge/05 and not on a slide. This is the biggest single missing piece.
- **Slide 10 (B1) Coates London trading floor** is equity HFT. An RQS bond audience will ask "why should I believe my Treasury PM's cortisol tracks my credit PM's cortisol?" Presenter needs a bond-specific anchor: either a reference to Duffie 2010 slow-moving capital as the *macro* behavioral aggregation in fixed income, or a data slide showing bond-PM cortisol/HRV equivalent.
- **Slide 13 recommendations** are asset-class-agnostic. That's not necessarily wrong, but an RQS bond audience expects at least one recommendation tailored to the bond-specific channels: e.g. "premortem protocol for duration-extension trades during VIX>25 / credit-spread-widening windows" — that's a bond-native recommendation, rather than a generic cooling-off gate.

## Recommendations slide — credibility check

**Rec #1 — Per-analyst confidence normalization.** Solid. Internally grounded, low implementation cost, statistically straightforward. Only gap: does the tool output change PM behavior? The deck needs a one-slide A/B test plan or a retrospective showing PMs who *did* use percentile-within-analyst data outperformed PMs who used absolute.

**Rec #2 — Tail-weighted sizing bands.** Medium credibility. The theorem is real; the empirical-fit check is internal-only; the critical missing piece is the backtested Sharpe uplift. Without that, this is a recommendation with directional support but no magnitude. RQS will not implement a sizing change without a quantified expected lift.

**Rec #3 — Stress-window decision protocol.** Credibility hurt by the Haynes 47% number. Mechanism is fine (Arnsten PFC attenuation), process literature is fine (Klein premortem, Kahneman Noise), but the effect-size claim leans on the least-robust evidence in the deck. Drop Haynes, lead with Pronovost central-line + Kahneman Noise underwriter-variability story. Also: define the trigger. VIX>X? Drawdown>Y%? Multi-condition gate? The deck doesn't say, and RQS will ask.

**Rec #4 — Sleep policy.** Low credibility as currently framed. Yoo 2007 is basic science with no PM-translation evidence. "Avoid major reallocations on sleep-deprived days" is fine as a principle but is currently unimplementable — no sleep-tracking infrastructure, no policy teeth. This reads as aspirational. Either (a) demote to "research direction," (b) propose a concrete pilot (opt-in wearable, N=20 PMs, pre-FOMC window, pre-registered endpoint), or (c) remove.

## Top 10 specific changes to make before showing

**1. Add an NLP validation appendix slide (highest priority).** The entire deck hinges on the extracted confidence scalar being a valid measurement. Show prompt, model, held-out κ, behavioral-outcome correlation. Without this, the presenter is one good question away from collapse. **Rationale:** addresses Q&A question #1; shores up the entire empirical stack.

**2. Rewrite slide 8 takeaway.** Change "The 2022 analyst note is a non-invasive biomarker of an HPA episode" to "The 2022 horizon compression is consistent with the behavioral signature of HPA-axis activation." **Rationale:** converts a clinical-validation claim the deck cannot defend into a hypothesis the deck can defend.

**3. Add a bond-market-translation slide between slides 9 and 10 (or fold into slide 3).** A one-slide table mapping each behavioral finding → bond-market channel with a primary citation from knowledge/05 (Duffie 2010, Brunnermeier-Pedersen 2009, He-Krishnamurthy 2013, Greenwood-Hanson 2013, Haddad-Moreira-Muir 2021). **Rationale:** closes the single largest gap for the bond audience; repositions the deck from "generic behavioral finance" to "bond-native behavioral pricing."

**4. Replace "five disciplines converge" with "five levels of description of a single HPA pathway."** Specifically on slide 3, slide 14, and anywhere "convergence is the argument" appears. **Rationale:** removes the strongest rhetorical-overclaim red flag; replaces with a mechanistic-integration claim that is defensible.

**5. Drop R²=0.55 from slide 10.** Keep the qualitative testosterone-risk-taking reference. **Rationale:** removes the single most suspicious effect-size claim in the deck.

**6. Replace Haynes 47% with Pronovost central-line result and add Urbach caveat.** On slide 13 rec #3. **Rationale:** removes the known-null-replication citation; leads with the more robust evidence.

**7. Add a pre-registration + multiple-comparisons slide to the main deck (not just the appendix).** Before the data slides. **Rationale:** pre-empts the single most predictable methodological attack; signals rigor to the skeptics early.

**8. Add a moderator-analysis slide for A1c.** Does horizon compression scale with tenure / working-memory proxy / coverage load, per Otto 2013? If it does, that's the clean falsifiable test the computational frame demands. If it doesn't, the presenter needs to own that and update. **Rationale:** turns the weakest causal-inference chain in the deck into its strongest, if the data supports it.

**9. Rewrite slide 1 hook to remove loaded language.** "Collapsed → statistically significant shortening," "exactly the moment → coinciding with," and add the effect size (how many standard deviations, what p-value, what N). **Rationale:** quantitative anchor on slide 1 signals to the audience that numbers drive the narrative, not the other way around.

**10. Add an AMH meta-frame slide, probably as slide 2 or integrated into slide 2.** Per knowledge/05's explicit recommendation. **Rationale:** gives the audience a rational-frictions-compatible meta-frame up front, which lowers the skeptic's resistance throughout. The deck currently provides no such off-ramp, so every behavioral claim has to be defended in isolation.

## One-line verdict

I would come away respecting the presenter's literature depth and originality of synthesis, but I would not let this version of the deck make load-bearing recommendations on my desk — the NLP validation, multiple-comparisons handling, bond-market translation, and claim-calibration need to be tightened before the science-rigor impression survives the first ten minutes of Q&A.
